Drug Details
General Information of the Drug (ID: DR7601) | ||||
---|---|---|---|---|
Name |
IL-24
|
|||
Molecular Type |
Protein
|
|||
Disease | Colon cancer [ICD-11: 2B90] | Investigative | [1] |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
Luteolin | Abrus precatorius | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Molecule(s)
Regulation |
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Cleavage | CASP8 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | L-02 | CVCL_6926 | Ovarian cancer | Homo sapiens | ||
MHCC97-H | CVCL_4972 | Adult hepatocellular carcinoma | Homo sapiens | |||
Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | |||
PLC/PRF/5 | CVCL_0485 | Adult hepatocellular carcinoma | Homo sapiens | |||
Hep 3B2.1-7 | CVCL_0326 | Childhood hepatocellular carcinoma | Homo sapiens | |||
In-vivo Model | The xenograft model was established by subcutaneously injection of 4*106 MHCC97-H cells into the right flank of these female BALB/c nude mice (5 weeks old). | |||||
Experimental
Result(s) |
Luteolin enhances the antitumor efficacy of oncolytic vaccinia virus that harbors IL-24 gene in liver cancer cells. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Angiotensin-converting enzyme 2 (ACE2) | Molecule Info | [3] | |
KEGG Pathway | Renin-angiotensin system | Click to Show/Hide | ||
2 | Protein digestion and absorption | |||
Reactome | Metabolism of Angiotensinogen to Angiotensins | Click to Show/Hide | ||
WikiPathways | ACE Inhibitor Pathway | Click to Show/Hide | ||
2 | Metabolism of Angiotensinogen to Angiotensins |


